In the Claims:

Amend claim 1 as follows:

Claim 1. (currently amended) A compound of Formula I, and pharmaceutically acceptable salts thereof,



Formula I

wherein:

R_1 is $-(CR^aR^b)_n-X$;

R^a, R^b are each independently selected from the group consisting of H, C_{1-6} alkyl; each of said C_{1-6} alkyl being optionally substituted with one to six same or different halogen;

X is H or C_{1-6} alkyl; said C_{1-6} alkyl being optionally substituted with a member selected from the group consisting of (1) one to six same or different halogen or hydroxy, (2) heteroaryl, (3) non-aromatic heterocyclic ring and (4) a member selected from Group A;

n is 1-6;

Group A is a member selected from the group consisting of halogen, CN, OR^x, $N^+R^cR^dR^e[T^-]$, NR^cR^d, COR^c, CO_2R^x, $CONR^xR^y$ and $S(O)_mR^c$;
R^x and R^y are independently H or C_{1-6} alkyl;
R^c, R^d and R^e are independently C_{1-6} alkyl;

m is 0-2

T^- is halogen, $CF_3SO_3^-$ or $CH_3SO_3^-$;

R_2 and R_5 are independently halogen or H;

R_3 and R_4 are each independently selected from the group consisting of H, halogen and C_{1-6} alkyl; said C_{1-6} alkyl can be optionally substituted with one to six same or different halogen;

Q is a member selected from the group consisting of











F_1 is CH or N;

R_6 is selected from the group consisting of H, halogen, NR^fR^g, SR^n and a five-membered heteroaryl containing one to two of the same or different heteroatoms selected from the group consisting of O, S and N;

R^f and R^g are independently H, C_{1-6} alkyl or C_{1-6} alkyl; said C_{1-6} alkyl optionally substituted with OR^h or CO_2R^h;

R^h and R^i are independently H or C_{1-6} alkyl;

R^n is C_{1-6} alkyl optionally substituted with CO_2R^h;

R_7 is H, or CO_2R^h;

R_8 is H, COR^h, CO_2R^h or C_{1-6} alkyl; said C_{1-6} alkyl optionally substituted with OR^h;

R_9 is H, halogen, heteroaryl, phenyl, phenyl substituted with a halogen group, phenyl substituted with a methanesulfonyl group, COR^h, CO_2R^h, C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-4} alkynyl; said C_{2-4} alkynyl optionally substituted with C_{1-6} cycloalkyl;

R_{10} and R_{11} are independently H, NO_2 or NR^hR^i

R_{12} is H, CO_2R^h or C_{1-2} alkyl; said C_{1-2} alkyl optionally substituted with phenyl;

R_{13} and R_{14} are independently selected from the group consisting of H, OR^h, $CONR^jR^k$, NR^lR^m and pyrrolidine; wherein said pyrrolidine is attached at the nitrogen atom;

R^j and R^k are independently H or C_{1-6} alkyl optionally substituted with phenyl;

R^l and R^m are independently C_{1-6} alkyl;

R_{15} and R_{16} are independently selected from the group consisting of H, OR^h, phenyl, pyridyl and C_{1-6} alkyl; said C_{1-6} alkyl optionally substituted with CO_2R^h;

R_{17} and R_{18} are independently selected from the group consisting of halogen, NR^lR^m, SR^h and morpholine; wherein said morpholine is attached at the nitrogen atom;

R_{19} is selected from the group consisting of H, phenyl, C_{2-6} alkenyl and C_{1-6} alkyl; said C_{1-6} alkyl optionally substituted with one to six same or different halogen, CO_2R^h, $CONR^hR^i$, pyridyl and one to three phenyl groups; wherein in the case of C_{1-6} alkyl substituted with one phenyl group, said phenyl group is optionally substituted with a member selected from the group consisting of halogen, $PO(OR^h)_2$, CO_2R^h, SO_2R^n and $CONR^hR^i$;

R^n is C_{1-6} alkyl;

R_{20} and R_{21} are independently H or halogen;

R_{22} is C_{1-6} alkyl;

R_{23} and R_{24} are independently H or C_{1-6} alkyl;

R_{25} is C_{1-6} cycloalkyl or C_{1-6} alkyl; said C_{1-6} alkyl group optionally substituted with a member selected from the group consisting of CO_2R^h, $PhCO_2R^h$ and one to six same or different halogens;

~~R_{26} is selected from the group consisting of H, halogen, C_{1-6} alkyl; C_{2-6} alkenyl, OR^h and COR^h; said C_{2-6} alkenyl being optionally substituted with OR^h;~~

~~R_{27} is H, OR^h or CO_2R^h;~~

~~R_{28} is CO_2R^h;~~

~~R_{29} is H or halogen;~~

heteroaryl is a 5- or 6-membered aromatic ring containing at least one and up to four non-carbon atoms selected from the group consisting of O, N and S;

non-aromatic heterocyclic ring is a 3 to 7-membered non-aromatic ring containing at least one and up to four non-carbon atoms selected from the group consisting of O, N and S; and

p is 0-2.

Claim 2. (original) A compound of claim 1 wherein heteroaryl is selected from the group consisting of pyridyl, thiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,4-oxadiazol-5-one and tetrazole.

Claim 3. (original) A compound of claim 1 wherein non-aromatic heterocyclic ring is selected from the group consisting of pyrrolidine and piperidine.

Claim 4. (original) A compound of claim 1 wherein:

R^a and R^b are hydrogen.

Claim 5. (original) A compound of claim 1 wherein:

R_1 is $-(CH_2)_n$-X and n is 2-4.

Claim 6. (original) A compound in claim 1 wherein R_3 and R_4 are each independently selected from the group consisting of H, fluorine and C_{1-2} alkyl; said C_{1-2} alkyl being optionally substituted with one to three fluorine atoms.

Claim 7. (original) A compound in claim 1 wherein:

R_1 is 3-methyl-2-butyl or $-(CH_2)_n$-X; wherein n is 2-4;

X is a member selected from the group consisting of
-F, -CN, $-SR^c$, $-SO_2R^c$, $-OR^x$, $-COR^c$,CO_2R^x, $CONR^xR^y$,
$[NR^cR^dR^e][T^-]$,



R^c, R^d and R^e are independently C_{1-4} alkyl; and

R^x and R^y are independently H or C_{1-4} alkyl.

Claim 8. (original) A compound of claim 1 wherein:

R_2 and R_5 are independently H.

Claim 9. (original) A method for treating mammals infected with RSV, and in need thereof, which comprises administering to said mammal a therapeutically effective amount of one or more of the aforementioned compounds as claimed in any one of claims 1-8.

Claim 10. (original) A pharmaceutical composition which comprises a therapeutically effective amount of one or more of the aforementioned compounds as claimed in any one of claims 1-8, and a pharmaceutically acceptable carrier.